Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 16/20 | 0.66 |
| ▸ | CYSLTR1 | Q9Y271 | 16/20 | 0.66 |
| ▸ | PPARG | P37231 | 3/20 | 0.58 |
| ▸ | PPARD | Q03181 | 3/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tipelukast SCHEMBL154898 | 0.93 | CYSLTR2 (0.78) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| Tipelukast SCHEMBL29359070 | 0.93 | CYSLTR2 (0.78) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL18590691 | 0.91 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL15032724 | 0.88 | PPARG (0.60) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL2419557 | 0.86 | CYSLTR2 (0.62) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL9178402 | 0.85 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL9342993 | 0.85 | CYSLTR2 (0.69) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL6275306 | 0.84 | CYSLTR2 (0.62) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL12280239 | 0.84 | PPARG (0.63) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL6279584 | 0.83 | CYSLTR2 (0.62) | CYSLTR2CYSLTR1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021275-A1 | METHOD OF TREATING IDIOPATHIC PULMONARY FIBROSIS | MEDICINOVA, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20170065544-A1 | METHOD OF TREATING IDIOPATHIC PULMONARY FIBROSIS | MEDICINOVA, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-9346754-B2 | Method of treating advanced non-alcoholic steatohepatitis | MEDICINOVA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150321989-A1 | METHOD OF TREATING IDIOPATHIC PULMONARY FIBROSIS | MEDICINOVA, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322004-A1 | METHOD OF TREATING ADVANCED NON-ALCOHOLIC STEATOHEPATITIS | MEDICINOVA, INC. (US) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021275-A1 | METHOD OF TREATING IDIOPATHIC PULMONARY FIBROSIS | CCL11, CFTR, ELANE | CYSLTR2 301/4885CYSLTR1 229/4885PPARG 793/4885 |
| US-20170065544-A1 | METHOD OF TREATING IDIOPATHIC PULMONARY FIBROSIS | CCL11, CFTR, ELANE | CYSLTR2 301/4885CYSLTR1 229/4885PPARG 793/4885 |
| US-20150321989-A1 | METHOD OF TREATING IDIOPATHIC PULMONARY FIBROSIS | CCL11, CFTR, ELANE | CYSLTR2 301/4885CYSLTR1 229/4885PPARG 793/4885 |
| US-20150322004-A1 | METHOD OF TREATING ADVANCED NON-ALCOHOLIC STEATOHEPATITIS | SLC10A1, CYP27A1, GOT2 | CYSLTR2 1496/4885CYSLTR1 1320/4885PPARG 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.